TY - JOUR
T1 - Two Years of Genomic Surveillance in Belgium during the SARS-CoV-2 Pandemic to Attain Country-Wide Coverage and Monitor the Introduction and Spread of Emerging Variants
AU - COVID-19 Genomics Belgium Consortium
AU - Cuypers, Lize
AU - Dellicour, Simon
AU - Hong, Samuel L
AU - Potter, Barney I
AU - Verhasselt, Bruno
AU - Vereecke, Nick
AU - Lambrechts, Laurens
AU - Durkin, Keith
AU - Bours, Vincent
AU - Klamer, Sofieke
AU - Bayon-Vicente, Guillaume
AU - Vael, Carl
AU - Ariën, Kevin K
AU - De Mendonca, Ricardo
AU - Soetens, Oriane
AU - Michel, Charlotte
AU - Bearzatto, Bertrand
AU - Naesens, Reinout
AU - Gras, Jeremie
AU - Vankeerberghen, Anne
AU - Matheeussen, Veerle
AU - Martens, Geert
AU - Obbels, Dagmar
AU - Lemmens, Ann
AU - Van den Poel, Bea
AU - Van Even, Ellen
AU - De Rauw, Klara
AU - Waumans, Luc
AU - Reynders, Marijke
AU - Degosserie, Jonathan
AU - Maes, Piet
AU - André, Emmanuel
AU - Baele, Guy
N1 - Copyright:
This record is sourced from MEDLINE/PubMed, a database of the U.S. National Library of Medicine
PY - 2022/10/20
Y1 - 2022/10/20
N2 - An adequate SARS-CoV-2 genomic surveillance strategy has proven to be essential for countries to obtain a thorough understanding of the variants and lineages being imported and successfully established within their borders. During 2020, genomic surveillance in Belgium was not structurally implemented but performed by individual research laboratories that had to acquire the necessary funds themselves to perform this important task. At the start of 2021, a nationwide genomic surveillance consortium was established in Belgium to markedly increase the country's genomic sequencing efforts (both in terms of intensity and representativeness), to perform quality control among participating laboratories, and to enable coordination and collaboration of research projects and publications. We here discuss the genomic surveillance efforts in Belgium before and after the establishment of its genomic sequencing consortium, provide an overview of the specifics of the consortium, and explore more details regarding the scientific studies that have been published as a result of the increased number of Belgian SARS-CoV-2 genomes that have become available.
AB - An adequate SARS-CoV-2 genomic surveillance strategy has proven to be essential for countries to obtain a thorough understanding of the variants and lineages being imported and successfully established within their borders. During 2020, genomic surveillance in Belgium was not structurally implemented but performed by individual research laboratories that had to acquire the necessary funds themselves to perform this important task. At the start of 2021, a nationwide genomic surveillance consortium was established in Belgium to markedly increase the country's genomic sequencing efforts (both in terms of intensity and representativeness), to perform quality control among participating laboratories, and to enable coordination and collaboration of research projects and publications. We here discuss the genomic surveillance efforts in Belgium before and after the establishment of its genomic sequencing consortium, provide an overview of the specifics of the consortium, and explore more details regarding the scientific studies that have been published as a result of the increased number of Belgian SARS-CoV-2 genomes that have become available.
KW - Humans
KW - Belgium/epidemiology
KW - COVID-19/epidemiology
KW - Genome, Viral
KW - Genomics
KW - Pandemics
KW - SARS-CoV-2/genetics
KW - High-Throughput Nucleotide Sequencing
UR - http://www.scopus.com/inward/record.url?scp=85140932525&partnerID=8YFLogxK
U2 - 10.3390/v14102301
DO - 10.3390/v14102301
M3 - Article
C2 - 36298856
VL - 14
JO - Viruses
JF - Viruses
SN - 1999-4915
IS - 10
M1 - 2301
ER -